

This material is an English translation of the press release announced on August 28, 2015 in Japanese, and the Japanese release is given priority about the content and the interpretation.

---

August 28, 2015

**Notification of the commencement of the Phase II clinical study of HP-3150 in Japan for  
“Lower back pain” (an analgesic transdermal drug containing NSAIDs)**

Hisamitsu Pharmaceutical Co., Inc. (Head Office: Tosu city, Saga prefecture, Japan; Chairman and CEO: Hirotaka Nakatomi, hereinafter referred to as Hisamitsu) hereby announces that it has commenced of the Phase II clinical study for “Lower back pain” in Japan for an analgesic transdermal patch containing NSAIDs (Development code: HP-3150, hereinafter referred to as “the product”).

The product is a systemic transdermal drug developed utilizing Hisamitsu’s TDDS (Transdermal Drug Delivery System) technology and containing the active ingredient NSAIDs (Non-Steroidal Anti-Inflammatory Drugs).

In the Phase II clinical study, the efficacy and safety of administration of the product will be compared with a placebo in patients suffering from lower back pain. We expect the product to be a new option for the treatment of such patients who will benefit from its long-lasting effect by means of maintaining a stable blood concentration.

A Phase II/III of the product (clinical study compared with a placebo and long-term clinical study) was commenced in June for “cancer pain”.

We aim to initiate a Phase III clinical study during FY 2017.